Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] | MicrobiomeTrials← Back to trialsNCT05536973
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2022-08-23Est. Completion: 2024-08-26
Enrollment target: 69 participants Locations- Adverum Clinical Site 178, Phoenix, Arizona, United States
- Adverum Clinical Site 126, Phoenix, Arizona, United States
- Adverum Clinical Site 159, Tucson, Arizona, United States
- Adverum Clinical Site 100, Beverly Hills, California, United States
- Adverum Clinical Site 172, Encino, California, United States
- Adverum Clinical Site 169, Fullerton, California, United States
- Adverum Clinical Site 170, Pasadena, California, United States
- Adverum Clinical Site 174, Poway, California, United States
- Adverum Clinical Site 164, Riverside, California, United States
- Adverum Clinical Site 166, Sacramento, California, United States
- Adverum Clinical Site 175, Santa Barbara, California, United States
- Adverum Clinical Site 116, Lakewood, Colorado, United States
- Adverum Clinical Site 165, Waterford, Connecticut, United States
- Adverum Clinical Site 124, Deerfield Beach, Florida, United States
- Adverum Clinical Site 176, Fort Lauderdale, Florida, United States
- Adverum Clinical Site 168, Jacksonville, Florida, United States
Other microbiome trials you might be interested in
Neovascular Age-related Macular Degeneration (nAMD)
This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, …
Santa Ana, United StatesEst. completion Oct 16, 2026
Macular DegenerationWet Macular DegenerationRetinal DegenerationRetinal DiseasesEye Diseases
The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients pr…
Bordeaux, France
Adverum Clinical Site 149, ‘Aiea, Hawaii, United StatesAdverum Clinical Site 167, Detroit, Michigan, United StatesAdverum Clinical Site 161, Royal Oak, Michigan, United StatesAdverum Clinical Site 163, Southaven, Mississippi, United StatesAdverum Clinical Site 177, Omaha, Nebraska, United StatesAdverum Clinical Site 119, Reno, Nevada, United StatesAdverum Clinical Site 146, Cherry Hill, New Jersey, United StatesAdverum Clinical Site 171, Teaneck, New Jersey, United StatesAdverum Clinical Site 122, West Columbia, South Carolina, United StatesAdverum Clinical Site 144, Rapid City, South Dakota, United StatesAdverum Clinical Site 101, Nashville, Tennessee, United StatesAdverum Clinical Site 123, Abilene, Texas, United StatesAdverum Clinical Site 154, Austin, Texas, United StatesAdverum Clinical Site 108, Bellaire, Texas, United StatesAdverum Clinical Site 162, McAllen, Texas, United StatesAdverum Clinical Site 151, San Antonio, Texas, United StatesAdverum Clinical Site 107, The Woodlands, Texas, United StatesAdverum Clinical Site 152, Morgantown, West Virginia, United StatesAdverum Clinical Site 502, Nantes, Loire-Atlantique, FranceAdverum Clinical Site 501, Lyon, Rhône, FranceAdverum Clinical Site 500, Créteil, Val-de-Marne, FranceAdverum Clinical Site 600, London, United KingdomAdverum Clinical Site 601, Oxford, United KingdomCompleted Dec 2015
Neovascular Age-Related Macular Degeneration
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 m…
Phoenix, United StatesEst. completion Dec 31, 2029